NASDAQ:ONCS - OncoSec Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.64 -0.01 (-1.54 %)
(As of 12/19/2018 10:54 AM ET)
Previous Close$0.65
Today's Range$0.63 - $0.66
52-Week Range$0.63 - $2.21
Volume10,000 shs
Average Volume2.19 million shs
Market Capitalization$45.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
Previous Symbol
CUSIPN/A
Phone855-662-6732

Debt

Debt-to-Equity RatioN/A
Current Ratio5.42
Quick Ratio4.90

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.39 per share
Price / Book1.64

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-39,130,000.00
Net MarginsN/A
Return on Equity-151.71%
Return on Assets-123.34%

Miscellaneous

Employees34
Outstanding Shares64,510,000
Market Cap$45.15 million
OptionableNot Optionable

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) issued its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. View OncoSec Medical's Earnings History.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release their next quarterly earnings announcement on Friday, March 8th 2019. View Earnings Estimates for OncoSec Medical.

What price target have analysts set for ONCS?

4 brokerages have issued 12-month target prices for OncoSec Medical's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate OncoSec Medical's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 512.7% from the stock's current price. View Analyst Price Targets for OncoSec Medical.

What is the consensus analysts' recommendation for OncoSec Medical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.

Has OncoSec Medical been receiving favorable news coverage?

Headlines about ONCS stock have been trending positive on Wednesday, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. OncoSec Medical earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.

Who are some of OncoSec Medical's key competitors?

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the folowing people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 54)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 38)
  • Ms. Sara M. Bonstein, CFO & COO (Age 37)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.08%) and Nexthera Capital LP (2.34%). Company insiders that own OncoSec Medical stock include Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon and Richard B Slansky. View Institutional Ownership Trends for OncoSec Medical.

Which institutional investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Nexthera Capital LP and Point72 Asset Management L.P.. Company insiders that have sold OncoSec Medical company stock in the last year include Avtar S Dhillon, Punit Dhillon and Richard B Slansky. View Insider Buying and Selling for OncoSec Medical.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $0.6528.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $45.15 million. OncoSec Medical employs 34 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is http://www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]


MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  397
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel